Patents Assigned to Cytokinetics, Inc.
  • Certain amino-pyrimidines, compositions thereof, and methods for their use
    Patent number: 9018223
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 28, 2015
    Assignee: Cytokinetics, Inc.
    Inventors: Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang
  • Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
    Patent number: 9012450
    Abstract: Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: April 21, 2015
    Assignees: Global Blood Therapeutics, Inc., Cytokinetics, Inc., The Regents of the University of California
    Inventors: Brian Metcalf, Chihyuan Chuang, Jeffrey Warrington, Kumar Paulvannan, Matthew P. Jacobson, Lan Hua, Bradley Morgan
  • Amino-pyridazine skeletal muscle modulators
    Patent number: 8969346
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: March 3, 2015
    Assignee: Cytokinetics, Inc.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Scott Collibee, Chihyuan Chuang, Jeff Gardina, Bradley P. Morgan, Alex R. Muci, Xiangping Qian, Jeffrey M Warrington, Zhe Yang, Pu-Ping Lu, Antonio Romero
  • Certain amino-pyrimidines, compositions thereof, and methods for their use
    Patent number: 8962632
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: February 24, 2015
    Assignee: Cytokinetics, Inc.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Certain chemical entities, compositions, and methods
    Patent number: 8895582
    Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: November 25, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Xiangping Qian, Chihyuan (Grace) Chuang, Pu-Ping Lu, Bing Yao, Qing (Kevin) Lu, Hong Jiang, Wenyue Wang, Bradley P. Morgan, David J. Morgans, Jr.
  • CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE
    Publication number: 20140330011
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 6, 2014
    Publication date: November 6, 2014
    Applicant: CYTOKINETICS, INC
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Chihyuan Chuang, Scott Collibee, Pu-Ping Lu, Bradley Morgan, Alex Muci, Xiangping Qian, Jeffrey Warrington, Zhe Yang
  • Certain chemical entities, compositions and methods
    Patent number: 8871768
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: October 28, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Bradley P. Morgan, David J. Morgans, Alex Muci, Pu-Ping Lu, Erica A. Kraynack, Todd Tochimoto
  • Ureas and their use in the treatment of heart failure
    Patent number: 8871769
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: October 28, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans
  • HETEROCYCLIC COMPOUNDS AND THEIR USES
    Publication number: 20140309235
    Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 16, 2014
    Applicants: CYTOKINETICS, INC., AMGEN INC.
    Inventors: Mingda Bi, Robert Kuehl
  • Imidazole-benzamide anti-cancer agents
    Patent number: 8772507
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: July 8, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Xiangping Qian, Andrew I. McDonald, Han-Jie Zhou, Luke W. Ashcraft, Bing Yao, Hong Jiang, Jennifer Kuo Chen Huang, Jianchao Wang, David J. Morgans, Jr., Bradley P. Morgan, Gustave Bergnes, Dashyant Dhanak, Steven D. Knight, Nicholas D. Adams, Cynthia A. Parrish, Kevin Duffy, Duke Fitch, Rosanna Tedesco
  • Certain chemical entities, compositions, and methods
    Patent number: 8759374
    Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: June 24, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Xiangping Qian, Chihyuan (Grace) Chuang, Pu-Ping Lu, Bing Yao, Qing (Kevin) Lu, Hong Jiang, Wenyue Wang, Bradley P. Morgan, David J. Morgans, Jr.
  • Certain heterocycles, compositions thereof, and methods for their use
    Patent number: 8759380
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: June 24, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Chihyuan Chuang, Scott Collibee, Pu-Ping Lu, Bradley Morgan, Alex Muci, Xiangping Qian, Jeffrey Warrington, Zhe Yang
  • Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
    Patent number: 8716291
    Abstract: Provided are compounds of Formula I and compounds of Formula II: and pharmaceutically acceptable salts thereof, and methods for their use.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: May 6, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Aaron Hinken, Fady Malik, Malar Pannirselvam, Alan Russell
  • Certain heterocycles, compositions thereof, and methods for their use
    Patent number: 8686007
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: April 1, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Chihyuan Chuang, Scott Collibee, Pu-Ping Lu, Bradley Morgan, Alex Muci, Xiangping Qian, Jeffrey Warrington, Zhe Yang
  • Methods and compositions utilizing quinazolinones
    Patent number: 8658656
    Abstract: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: February 25, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Jeffrey T. Finer, Gustav S Bergnes, Whitney W. Smith, John C. Chabala, Bainian Feng
  • Certain chemical entities, compositions, and methods
    Patent number: 8653081
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: February 18, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Bradley P. Morgan, Erica A. Kraynack, Pu-Ping Lu, Alex Muci, David J. Morgans
  • Compounds, compositions and methods
    Patent number: 8633236
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: January 21, 2014
    Assignee: Cytokinetics, Inc.
    Inventors: Andrew McDonald, Gustave Bergnes, Bainian Feng, David J. Morgans, Jr., Steven David Knight, Kenneth A. Newlander, Dashyant Dhanak, Christopher A. Brook
  • Heterocyclic sulfonamides
    Patent number: 8604025
    Abstract: Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: December 10, 2013
    Assignee: Cytokinetics, Inc.
    Inventors: Bradley Paul Morgan, Fady Malik, Erica Anne Kraynack, Alexander Ramon Muci, Xiangping Qian, David J. Morgans, Jr.
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
    Publication number: 20130324549
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: May 17, 2013
    Publication date: December 5, 2013
    Applicant: Cytokinetics, Inc.
    Inventors: Bradley P. MORGAN, David J. Morgans, Alex Muci, Pu-Ping Lu, Erica A. Kraynack, Todd Tochimoto
  • HETEROCYCLIC SULFONAMIDES
    Publication number: 20130267537
    Abstract: Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Application
    Filed: February 5, 2013
    Publication date: October 10, 2013
    Applicant: Cytokinetics, Inc.
    Inventors: Bradley Paul MORGAN, Fady MALIK, Erica Anne KRAYNACK, Alexander Ramon MUCI, Xiangping QIAN, David J. MORGANS, JR.